atai Life Sciences to Participate in Upcoming November Investor Conferences
November 05 2021 - 4:30PM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced that it will
participate in the following upcoming investor conferences in
November:
Presentation details can be found below:
- Berenberg US CEO Conference 2021Format: 1x1
MeetingsDates: Tuesday, November 9th, 2021 – Wednesday, November
10th, 2021
- Credit Suisse 30th Annual Healthcare
ConferenceFormat: Fireside ChatDate and Time: Thursday,
November 11th, 2021, 9:40 a.m. ETWebcast Link:
https://kvgo.com/cs-2021-healthcare-conf/atai-life-sciences-nov
- 12th Annual Jefferies
London Healthcare ConferenceFormat: Fireside ChatDate and
Time: Thursday, November 18th, 2021, 8:00 a.m. ETWebcast Link:
https://wsw.com/webcast/jeff201/atai/1818738
The presentations and archived webcasts will also be accessible
in the Events section of atai’s website.
About atai Life Sciences atai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape. atai is dedicated to
acquiring, incubating and efficiently developing innovative
therapeutics to treat depression, anxiety, addiction, and other
mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's mission is to bridge the gap between what the mental
healthcare system currently provides and what patients need. atai
is headquartered in Berlin, with offices in New York and London.
For more information, please visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. Forward-looking statements are
neither promises nor guarantees, but involve known and unknown
risks and uncertainties that could cause actual results to differ
materially from those projected, including, without limitation, the
important factors discussed under the caption “Risk Factors” in
atai's prospectus pursuant to Rule 424(b) filed with the U.S.
Securities and Exchange Commission (“SEC”) on June 21, 2021, as
such factors may be updated from time to time in atai's other
filings with the SEC. atai disclaims any obligation or undertaking
to update or revise any forward-looking statements contained in
this press release, other than to the extent required by applicable
law.
Contact Information
Investor Contact:Chad MesserVP, Investor Relations, atai Life
SciencesEmail: chad@atai.life
Media Contact:Camilla DormerVP, Communications, atai Life
SciencesEmail: camilla@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024